Significant Collaboration Transactions - Additional Information (Details) - USD ($) $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended			6 Months Ended
	Apr. 30, 2022	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]	Dec. 31, 2022
Business Acquisition [Line Items]
Consideration					$ 0
Income (Loss) from Equity Method Investments		$ (67)		$ (10,166)	(1,516)	$ (31,053)
Deferred revenue (includes $2,672 and $10,309 from related parties)		133,779			133,779			$ 141,497
Revenue, Remaining Performance Obligation, Amount		$ 115,100			$ 115,100			123,500
BiomEdit LLC [Member]
Business Acquisition [Line Items]
Consideration	$ 32,500		$ 4,000
Common units	3.9	0.7			0.7
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited	0.7		0.3
Carrying value of the equity method investment					$ 8,900
Allocated upfront non-cash consideration					2,200
Deferred revenue (includes $2,672 and $10,309 from related parties)		$ 7,900			7,900			$ 8,100
Deferred revenue, Revenue recognized		900			1,800
Additional preferred units issued			0.8
Additional non-cash consideration			$ 1,100
Revenue, Remaining Performance Obligation, Amount		$ 300			300
common unit retained			0.4
Series A Preferred Stock | BiomEdit LLC [Member]
Business Acquisition [Line Items]
Share Sold	6.7
Additional share	1.5
Income (Loss) from Equity Method Investments					$ 1,500
Allocated upfront non-cash consideration			$ 1,100
Additional preferred units issued	1.5

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.